Skip to main content
Equibles
ITHUF logo

ITHUF · iANTHUS CAPITAL HOLDINGS, INC.

Track ITHUF — free

Use ITHUF with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.00 0.00 (-10.87%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“While we believe that we have funding necessary for us to continue as a going concern, we may need to raise additional capital and there can be no assurance that such capital will be available to us on favorable terms, if at all. As such, these material circumstances cast substantial doubt on our ability to continue as a going concern for a period of no less than 12 months from the date of this report, and our unaudited interim condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$27.90M
Shares
6.97B

ITHUF metrics

66 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$27.90M

Price action

19 metrics
Price change (1W)
-12.8%
Price change (30D)
+7.9%
Price change (3M)
-18.0%
Price change (6M)
+2.5%
Price change (YTD)
-18.0%
Price change (1Y)
-18.0%
Trailing year
Price change (5Y)
-98.8%
52-week high
$0.01
52-week low
$0.00
Change from 52-week high
-54.4%
Change from 52-week low
+7.9%
Annualized volatility
190.1%
Beta
0.2
RSI (14D)
46.0
Price vs SMA 50
-7.6%
Price vs SMA 200
-14.5%
Avg volume (3M)
151,025
Relative volume
0.2
Average dollar volume
$678

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
6.97B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.6×
reciprocal yield 62.5%
EV / EBITDA
33.0×
reciprocal yield 3.0%
EV / EBIT
—
P / sales
0.2×
reciprocal yield 500.2%
P / book
—
FCF yield
-80.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-198.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.5×
reciprocal yield 67.1%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 63.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
120.1×
reciprocal yield 0.8%
EV / EBITDA historical average (5Y)
113.9×
reciprocal yield 0.9%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
44.9%
Operating margin
-9.0%
Trailing 12 months
Net margin
-39.7%
Gross profit (TTM)
$62.69M
Operating profit (TTM)
−$12.61M
Net income (TTM)
−$55.37M
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
-16.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.28

Growth

11 metrics
Revenue growth YoY
+0.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$139.54M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.2%
Year over year · more shares
Revenue CAGR (3Y)
-4.1%
Revenue CAGR (5Y)
-1.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-21.4%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
$6.75M
Free cash flow (TTM)
−$22.41M
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
28.9
Return on invested capital
—
Trailing 12 months
Net cash
−$195.27M
Latest balance sheet
Cash & equivalents
$8.27M
Total assets
$258.43M
Total debt
$203.55M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.36M
Capital expenditures (TTM)
$21.05M
R&D (TTM)
—
SG&A (TTM)
$56.14M
Stock compensation (TTM)
$1.81M
R&D / revenue
—
Stock compensation / revenue
1.3%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
30 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1643154 CUSIP 45074T102 Visit website Investor relations